aTyr updates efzofitimod timing

1/ aTyr Pharma said on Sept. 1 it now expects feedback from the U.S. Food and Drug Administration by mid-September 2026 on the protocol it submitted in June for a planned phase 3 study of efzofitimod in pulmonary sarcoidosis. (investors.atyrpharma.com) 2/ The update was about timing, not new efficacy data. aTyr’s notice did not report fresh clinical results; it said only that, based on FDA feedback, the company anticipates a response by mid-September. (investors.atyrpharma.com) 3/ The planned study is aimed at patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, according to aTyr’s prior and current disclosures. In May, the company said it would pursue this path after a Type C meeting with the FDA. (investors.atyrpharma.com) 4/ The trial design aTyr has outlined is specific. The company said the planned phase 3 study is expected to be global, randomized, double-blind and placebo-controlled, testing intravenous efzofitimod 5.0 mg/kg every three weeks for 17 doses over 54 weeks. (investors.atyrpharma.com) 5/ aTyr has also said the planned primary endpoint is forced vital capacity, or FVC, with King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint. That matters because it shows the company is trying a different late-stage setup after earlier phase 3 results. (investors.atyrpharma.com) 6/ The backdrop is important. In September 2025, aTyr said its phase 3 EFZO-FIT study in 268 pulmonary sarcoidosis patients did not meet its primary endpoint, which was change from baseline in mean daily oral corticosteroid dose at week 48. (investors.atyrpharma.com) 7/ After that result, aTyr disclosed additional analyses and a new regulatory path. In July 2026, the company said a subgroup of patients with restrictive lung disease showed what it called clinically meaningful benefit in FVC and multiple patient-reported outcomes at the 5.0 mg/kg dose versus placebo. (investors.atyrpharma.com) 8/ That subgroup analysis is part of why the current protocol matters. aTyr’s revised phase 3 plan focuses on restrictive lung disease within pulmonary sarcoidosis and shifts the lead outcome to lung function rather than steroid reduction. (investors.atyrpharma.com) 9/ The company has also tied its broader corporate plan to efzofitimod. On Aug. 7, aTyr said it had cut its workforce by about 60% and reprioritized operations to conserve capital and focus resources on the efzofitimod program in interstitial lung disease. (investors.atyrpharma.com) 10/ Cash is part of the story too. aTyr said on Aug. 7 that it ended the second quarter of 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments, and projected runway into late 2028 based on current operations. (investors.atyrpharma.com) 11/ For patients and clinicians, this Sept. 1 announcement does not change standard care on its own. It signals when the company expects a regulatory response on trial design, which is a prerequisite to starting the planned study, not evidence that the drug has been cleared for use. (investors.atyrpharma.com) 12/ The next concrete marker is mid-September 2026. aTyr said that is when it expects the FDA response on the protocol for the planned pulmonary sarcoidosis phase 3 study. Any clearer read on launch timing, enrollment, or site activation likely depends on what the agency says then. (investors.atyrpharma.com)